Treatment with cilengitide alone could not inhibit TGF-β1-induced phosphorylation of Smad2/3, but combined treatment may increase the efficacy of gefitinib to induce NSCLC cell death and inhibit the EMT process through the inhibition of Smad signaling. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.